53004-19-6

Usage

Uses

Used in Pharmaceutical Industry:
1H-Benzimidazole-2-carboxaldehyde,5-methoxy-1-methyl-(9CI) is used as a key intermediate in the synthesis of pharmaceutical drugs for [application reason]. Its unique structural properties make it a promising candidate for the development of new therapeutic agents.
Used in Research and Development:
1H-Benzimidazole-2-carboxaldehyde,5-methoxy-1-methyl-(9CI) is used as a research compound for studying its chemical properties, reactivity, and potential applications in various fields, including medicinal chemistry and drug discovery.

Upstream product

• 4887-81-4 6-methoxy-2-methyl-1H-benzo[d]imidazole 
• 74-88-4 methyl iodide 
• 20033-99-2 (5-methoxy-1H-benzimidazole-2-yl)-methanol 
• 102-51-2 4-methoxy-1,2-phenylenediamine 
• 68426-83-5 (5-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)methanol 

Downstream Products

• 1357162-32-3 C₂₀H₁₈N₂O₄ 
• 1357162-41-4 C₂₀H₁₈N₂O₄ 

Relevant academic research and scientific papers

PROBES FOR IMAGING HUNTINGTIN PROTEIN

Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use. Formula (I)

Synthesis of substituted benzimidazolyl curcumin mimics and their anticancer activity

A novel curcumin mimic library (14a-14h and 15a-15h) possessing variously substituted benzimidazole groups was synthesized through the aldol reaction of (E)-4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one (7) or (E)-4-(3-hydroxy-4- methoxyphenyl)but-3-en-2-one (13) with diversely substituted benzimidazolyl-2-carbaldehyde (12a-12h). The MTT assay of the cancer cells MCF-7, SH-SY5Y, HEP-G2, and H460 showed that compound 14c with IC50 of 1.0 and 1.9 μM has a strong inhibitory effect on the growth of SH-SY5Y and Hep-G2 cells, respectively, and that compound 15h with IC50 of 1.9 μM has a strong inhibitory effect on the growth of MCF-7 cancer cells.

6-(SUBSTITUTED)METHYLENE-PENICILLANIC AND 6-(SUBSTITUTED)HYDROXYMETHYL-PENICILLANIC ACIDS AND DERIVATIVES THEREOF

Beta-lactamase inhibiting compounds of the formula: or a pharmaceutically acceptable acid addition or carboxylate salt thereof; where n is zero, 1 or 2; X.3 is H or Br, R1 is H, the residue of certain carboxy-protecting groups or the residue of an ester group readily hydrolyzable in vivo; one of R12 and R13 is H and the other is vinyl, certain aryl, alkylthio, alkylsulfonyl or certain heterocyclyl, aminomethyl, thiocarboxamido or amidino groups; one or R2 and R3 is H and the other is as disclosed for the other of R12 and R13, or is Cl or CH2 OH, and R18 is H or certain acyl groups; intermediates useful in their production, methods for their preparation and use, and pharmaceutical compositions containing them